Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro.

Burke MJ, Walmsley R, Munsey TS, Smith AJ.

Toxicol In Vitro. 2019 Aug;58:178-186. doi: 10.1016/j.tiv.2019.03.026. Epub 2019 Mar 22.

PMID:
30910525
2.

Perforated cytomegalovirus pseudotumour.

Schauer C, Chong L, Hendry K, Kozman MA, Rajaratnam S, Walmsley R.

ANZ J Surg. 2019 Mar 12. doi: 10.1111/ans.15060. [Epub ahead of print] No abstract available.

PMID:
30861292
3.

Choice architecture interventions to improve diet and/or dietary behaviour by healthcare staff in high-income countries: a systematic review.

Al-Khudairy L, Uthman OA, Walmsley R, Johnson S, Oyebode O.

BMJ Open. 2019 Jan 23;9(1):e023687. doi: 10.1136/bmjopen-2018-023687.

4.

Choice architecture modifies fruit and vegetable purchasing in a university campus grocery store: time series modelling of a natural experiment.

Walmsley R, Jenkinson D, Saunders I, Howard T, Oyebode O.

BMC Public Health. 2018 Oct 1;18(1):1149. doi: 10.1186/s12889-018-6063-8.

5.

The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.

Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M.

J Gastroenterol Hepatol. 2018 May;33(5):1047-1052. doi: 10.1111/jgh.14041. Epub 2018 Feb 14.

PMID:
29105142
6.

The influence of exogenous metabolism on the specificity of in vitro mammalian genotoxicity tests.

Tate MJ, Walmsley RM.

Mutagenesis. 2017 Oct 17;32(5):491-499. doi: 10.1093/mutage/gex017.

PMID:
28992092
7.

Development of an in vitro PIG-A gene mutation assay in human cells.

Rees BJ, Tate M, Lynch AM, Thornton CA, Jenkins GJ, Walmsley RM, Johnson GE.

Mutagenesis. 2017 Mar 1;32(2):283-297. doi: 10.1093/mutage/gew059.

8.

Screening for delirium in specialist palliative care inpatient units: perceptions and outcomes.

Porteous A, Dewhurst F, Gray WK, Coulter P, Karandikar U, Kiltie R, Lowery L, MacCormick F, Paxton A, Pickard J, Rowley G, Vidrine J, Walmsley R, Waterfield K, Weiand D, Grogan E.

Int J Palliat Nurs. 2016 Sep 2;22(9):444-447.

PMID:
27666305
9.

"We are what our bacteria eat": The role of bacteria in personalizing nutrition therapy in gastrointestinal conditions.

Harvie R, Walmsley R, Schultz M; New Zealand Society of Gastroenterology.

J Gastroenterol Hepatol. 2017 Feb;32(2):352-357. doi: 10.1111/jgh.13462. Review.

PMID:
27248703
10.

New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.

Eliadou E, Day AS, Thompson-Fawcett MW, Gearry RB, Rowbotham DS, Walmsley R, Schultz M, Inns SJ; IBDNZ; New Zealand Society of Gastroenterology.

N Z Med J. 2015 Oct 16;128(1423):63-76.

PMID:
26645757
11.

Cytotoxicity and genotoxicity of urban particulate matter in mammalian cells.

Dumax-Vorzet AF, Tate M, Walmsley R, Elder RH, Povey AC.

Mutagenesis. 2015 Sep;30(5):621-33. doi: 10.1093/mutage/gev025. Epub 2015 Jun 25.

12.

Primary pleural epithelioid hemangioendothelioma mimicking as a posterior mediastinal tumor.

Wethasinghe J, Sood J, Walmsley R, Milne D, Jafer A, Gordon-Glassford N.

Respirol Case Rep. 2015 Jun;3(2):75-7. doi: 10.1002/rcr2.106. Epub 2015 May 18.

13.

The 'BlueScreen HC' assay as a decision making test in the genotoxicity assessment of flavour and fragrance materials.

Etter S, Birrell L, Cahill P, Scott H, Billinton N, Walmsley RM, Smith B.

Toxicol In Vitro. 2015 Oct;29(7):1425-35. doi: 10.1016/j.tiv.2015.05.005. Epub 2015 May 21.

PMID:
26003925
14.

Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.

Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB.

Inflamm Bowel Dis. 2015 Apr;21(4):824-31. doi: 10.1097/MIB.0000000000000341.

PMID:
25738372
15.

Ames positive boronic acids are not all eukaryotic genotoxins.

Scott H, Walmsley RM.

Mutat Res Genet Toxicol Environ Mutagen. 2015 Jan 1;777:68-72. doi: 10.1016/j.mrgentox.2014.12.002. Epub 2014 Dec 15.

PMID:
25726177
16.

pH-metric chemical speciation modeling and studies of in vitro antidiabetic effects of bis[(imidazolyl)carboxylato]oxidovanadium(IV) complexes.

Gundhla IZ, Walmsley RS, Ugirinema V, Mnonopi NO, Hosten E, Betz R, Frost CL, Tshentu ZR.

J Inorg Biochem. 2015 Apr;145:11-8. doi: 10.1016/j.jinorgbio.2014.12.019. Epub 2014 Dec 27.

PMID:
25594947
17.

Comment on an optimized patient-reported ulcerative colitis disease activity measure derived from the mayo score and the simple clinical colitis activity index.

Walmsley RS.

Inflamm Bowel Dis. 2014 Dec;20(12):E25-6. doi: 10.1097/MIB.0000000000000248. No abstract available.

PMID:
25374290
18.

Support and practical advice for the use of nutrition support teams.

Larsen S, Baskett R, Hill S, Walmsley RS.

Br J Nurs. 2014 Jun 26-Jul 9;23(12):636-40. doi: 10.12968/bjon.2014.23.12.636.

PMID:
25039626
19.

Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition.

Walmsley RS.

J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:113-7. doi: 10.1111/jgh.12345. Review.

PMID:
24251716
20.

The diagnostic yield of colonoscopy in patients with isolated abdominal pain.

Kueh SH, Zhou L, Walmsley RS.

N Z Med J. 2013 Sep 13;126(1382):36-44.

PMID:
24154768
21.

On the physician-completed and the patient-completed simple clinical colitis activity index (SCCAI).

Walmsley RS, Casey P.

J Crohns Colitis. 2013 Dec;7(11):930-1. doi: 10.1016/j.crohns.2013.06.007. Epub 2013 Jul 10. No abstract available.

PMID:
23849400
22.

The involvement of WT1 in the regulation of GADD45a in response to genotoxic stress.

Johnson D, Hastwell PW, Walmsley RM.

Mutagenesis. 2013 Jul;28(4):393-9. doi: 10.1093/mutage/get015. Epub 2013 Mar 9.

PMID:
23476008
23.

Flow cytometric 96-well microplate-based in vitro micronucleus assay with human TK6 cells: protocol optimization and transferability assessment.

Bryce SM, Avlasevich SL, Bemis JC, Tate M, Walmsley RM, Saad F, Van Dijck K, De Boeck M, Van Goethem F, Lukamowicz-Rajska M, Elhajouji A, Dertinger SD.

Environ Mol Mutagen. 2013 Apr;54(3):180-94. doi: 10.1002/em.21760. Epub 2013 Feb 27.

PMID:
23447390
24.

Histone-deacetylase inhibitors produce positive results in the GADD45a-GFP GreenScreen HC assay.

Johnson D, Walmsley R.

Mutat Res. 2013 Mar 18;751(2):96-100. doi: 10.1016/j.mrgentox.2012.12.009. Epub 2013 Jan 20.

PMID:
23340162
25.

Successful treatment of parenteral nutrition-associated liver disease in an adult by use of a fish oil-based lipid source.

Venecourt-Jackson E, Hill SJ, Walmsley RS.

Nutrition. 2013 Jan;29(1):356-8. doi: 10.1016/j.nut.2012.07.009. Epub 2012 Nov 7.

PMID:
23141119
26.

Development of a high-throughput Gaussia luciferase reporter assay for the activation of the GADD45a gene by mutagens, promutagens, clastogens, and aneugens.

Hughes C, Rabinowitz A, Tate M, Birrell L, Allsup J, Billinton N, Walmsley RM.

J Biomol Screen. 2012 Dec;17(10):1302-15. doi: 10.1177/1087057112453312. Epub 2012 Jul 10.

PMID:
22786892
27.

Nongenotoxic apoptosis inducers do not produce misleading positive results in the TK6 cell-based GADD45a-GFP genotoxicity assay.

Topham CH, Billinton N, Walmsley RM.

Toxicol Sci. 2012 Jul;128(1):79-91. doi: 10.1093/toxsci/kfs132. Epub 2012 Apr 5.

PMID:
22491427
28.

A call for collaboration on inflammatory bowel disease in New Zealand.

Walmsley R.

N Z Med J. 2012 Feb 10;125(1349):7-10. No abstract available.

PMID:
22327147
29.

The GADD45a-GFP GreenScreen HC assay.

Walmsley RM, Tate M.

Methods Mol Biol. 2012;817:231-50. doi: 10.1007/978-1-61779-421-6_12.

PMID:
22147576
30.

Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis.

Dean KE, Hikaka J, Huakau JT, Walmsley RS.

J Gastroenterol Hepatol. 2012 Mar;27(3):487-92. doi: 10.1111/j.1440-1746.2011.06958.x.

PMID:
22098019
31.

How accurate is in vitro prediction of carcinogenicity?

Walmsley RM, Billinton N.

Br J Pharmacol. 2011 Mar;162(6):1250-8. doi: 10.1111/j.1476-5381.2010.01131.x. Review.

32.

Use of methadone for uncontrolled pain: an alternative dosing regimen.

Walmsley R, Robson P, Lee MA.

J Pain Symptom Manage. 2010 Dec;40(6):e3-4. doi: 10.1016/j.jpainsymman.2010.09.003. Epub 2010 Oct 20. No abstract available.

PMID:
20965690
33.

New and emerging technologies for genetic toxicity testing.

Lynch AM, Sasaki JC, Elespuru R, Jacobson-Kram D, Thybaud V, De Boeck M, Aardema MJ, Aubrecht J, Benz RD, Dertinger SD, Douglas GR, White PA, Escobar PA, Fornace A Jr, Honma M, Naven RT, Rusling JF, Schiestl RH, Walmsley RM, Yamamura E, van Benthem J, Kim JH.

Environ Mol Mutagen. 2011 Apr;52(3):205-23. doi: 10.1002/em.20614. Epub 2010 Aug 25. Review.

PMID:
20740635
34.

New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease.

Schultz M, Gearry R, Walmsley R, Day AS, Fraser A, Wyeth J, Barclay M, Clover G, Whiteside C.

N Z Med J. 2010 May 14;123(1314):134-44. Review. No abstract available.

PMID:
20590012
35.

A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9).

Billinton N, Bruce S, Hansen JR, Hastwell PW, Jagger C, McComb C, Klug ML, Pant K, Rabinowitz A, Rees R, Tate M, Vinggaard AM, Walmsley RM.

Mutat Res. 2010 Jul 19;700(1-2):44-50. doi: 10.1016/j.mrgentox.2010.05.001. Epub 2010 May 7.

PMID:
20452458
36.
37.

GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests.

Birrell L, Cahill P, Hughes C, Tate M, Walmsley RM.

Mutat Res. 2010 Jan;695(1-2):87-95. doi: 10.1016/j.mrgentox.2009.12.008. Epub 2009 Dec 16.

PMID:
20006735
38.

Analysis of 75 marketed pharmaceuticals using the GADD45a-GFP 'GreenScreen HC' genotoxicity assay.

Hastwell PW, Webster TW, Tate M, Billinton N, Lynch AM, Harvey JS, Rees RW, Walmsley RM.

Mutagenesis. 2009 Sep;24(5):455-63. doi: 10.1093/mutage/gep029. Epub 2009 Jul 10.

PMID:
19592503
39.

Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals.

Knight AW, Little S, Houck K, Dix D, Judson R, Richard A, McCarroll N, Akerman G, Yang C, Birrell L, Walmsley RM.

Regul Toxicol Pharmacol. 2009 Nov;55(2):188-99. doi: 10.1016/j.yrtph.2009.07.004. Epub 2009 Jul 8.

PMID:
19591892
40.

Development and validation of a higher throughput screening approach to genotoxicity testing using the GADD45a-GFP GreenScreen HC assay.

Knight AW, Birrell L, Walmsley RM.

J Biomol Screen. 2009 Jan;14(1):16-30. doi: 10.1177/1087057108327065.

PMID:
19171918
41.

Genotoxic carcinogen or not genotoxic carcinogen? That is the question Re: Olaharski et al., "Validation of the GreenScreen GADD45alpha-GFP indicator assay with non-proprietary and proprietary compounds".

Walmsley RM, Billinton N.

Mutat Res. 2009 Jan;672(1):17-9; author reply 20. doi: 10.1016/j.mrgentox.2008.10.003. Epub 2008 Oct 19. No abstract available.

PMID:
19000775
42.

Sub-10 nm nanoimprint lithography by wafer bowing.

Wu W, Tong WM, Bartman J, Chen Y, Walmsley R, Yu Z, Xia Q, Park I, Picciotto C, Gao J, Wang SY, Morecroft D, Yang J, Berggren KK, Williams RS.

Nano Lett. 2008 Nov;8(11):3865-9. doi: 10.1021/nl802295n. Epub 2008 Oct 7.

PMID:
18837563
43.

Assessment of the genotoxicity of S9-generated metabolites using the GreenScreen HC GADD45a-GFP assay.

Jagger C, Tate M, Cahill PA, Hughes C, Knight AW, Billinton N, Walmsley RM.

Mutagenesis. 2009 Jan;24(1):35-50. doi: 10.1093/mutage/gen050. Epub 2008 Sep 11.

PMID:
18787182
44.

GADD45a-GFP GreenScreen HC genotoxicity screening assay.

Walmsley RM.

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):827-35. doi: 10.1517/17425255.4.6.827 . Review.

PMID:
18611122
45.

Interlaboratory assessment of the GreenScreen HC GADD45a-GFP genotoxicity screening assay: an enabling study for independent validation as an alternative method.

Billinton N, Hastwell PW, Beerens D, Birrell L, Ellis P, Maskell S, Webster TW, Windebank S, Woestenborghs F, Lynch AM, Scott AD, Tweats DJ, van Gompel J, Rees RW, Walmsley RM.

Mutat Res. 2008 May 31;653(1-2):23-33. doi: 10.1016/j.mrgentox.2008.02.011. Epub 2008 Mar 27.

PMID:
18450500
46.

Clear and present danger? The use of a yeast biosensor to monitor changes in the toxicity of industrial effluents subjected to oxidative colour removal treatments.

Keenan PO, Knight AW, Billinton N, Cahill PA, Dalrymple IM, Hawkyard CJ, Stratton-Campbell D, Walmsley RM.

J Environ Monit. 2007 Dec;9(12):1394-401. Epub 2007 Sep 26.

PMID:
18049779
47.
48.

Acute onset of ascites with clozapine-induced hepatitis.

Luo D, McColl P, Walmsley R.

Intern Med J. 2007 Mar;37(3):204-5. No abstract available.

PMID:
17316346
49.

Developmental regulation of an adhesin gene during cellular morphogenesis in the fungal pathogen Candida albicans.

Argimón S, Wishart JA, Leng R, Macaskill S, Mavor A, Alexandris T, Nicholls S, Knight AW, Enjalbert B, Walmsley R, Odds FC, Gow NA, Brown AJ.

Eukaryot Cell. 2007 Apr;6(4):682-92. Epub 2007 Feb 2.

50.

Genotoxicity screening: the slow march to the future.

Walmsley RM.

Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):261-8. Review.

PMID:
16922641

Supplemental Content

Loading ...
Support Center